{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:53:45Z","timestamp":1787003625256,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-D-110050"],"award-info":[{"award-number":["TSGH-D-110050"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-E-111231"],"award-info":[{"award-number":["TSGH-E-111231"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Affairs Bureau Ministry of National Defense, Taiwan","award":["MND-MAB-C-11116-111057"],"award-info":[{"award-number":["MND-MAB-C-11116-111057"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) caused by carbapenem-resistant\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    (CRAB) are both associated with significant morbidity and mortality in daily clinical practice, as well as in a critical care setting. It is unclear whether colistin susceptible-only\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    (CSO AB) is a unique phenotype separate from or a subset of CRAB-associated pneumonia. The aim of this study is to investigate the prevalence of CSO AB pneumonia and compare the presentation and outcome between CSO AB and CRAB-associated pneumonia in critically ill patients. This multicenter retrospective cohort study initially recruited 955 patients with CR-GNB pneumonia. After exclusion, 575 patients left who were ICU-admitted and had CRAB nosocomial pneumonia remained. Among them, 79 patients had CSO AB pneumonia, classified as the CSO AB group. The other 496 patients were classified as the CRAB group. We compared demographic characteristics, disease severity, and treatment outcomes between the two groups. The prevalence of CSO AB among all cases of CRAB pneumonia was 13.74% (79\/575). The CSO AB and CRAB groups had similar demographic characteristics and disease severities at initial presentation. The in-hospital mortality rate was 45.6% and 46.4% for CSO AB and CRAB groups, respectively (p\u2009=\u20090.991). The CSO AB group had significantly better clinical outcomes at day 7 (65.8% vs 52.4%, p\u2009=\u20090.036) but longer length of ICU stay (27\u00a0days vs 19\u00a0days, p\u2009=\u20090.043) compared to the CRAB group. However, other treatment outcomes, including clinical outcomes at day 14 and 28, mortality, microbiological eradication, ventilator weaning, and newly onset dialysis, were similar. In conclusion,\u00a0CSO AB accounted for 13.74% of all cases of CRAB pneumonia, and the clinical presentation and treatment outcomes of CSO AB and CRAB pneumonia were similar.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-26009-0","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T05:04:08Z","timestamp":1672808648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The prevalence, presentation and outcome of colistin susceptible-only Acinetobacter Baumannii-associated pneumonia in intensive care unit: a multicenter observational study"],"prefix":"10.1038","volume":"13","author":[{"given":"Sheng-Huei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Yao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau-Chyun","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Cheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yih","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Rong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Kan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"26009_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4161\/viru.19700","volume":"3","author":"A Howard","year":"2012","unstructured":"Howard, A., O\u2019Donoghue, M., Feeney, A. & Sleator, R. D. Acinetobacter baumannii: An emerging opportunistic pathogen. Virulence 3, 243\u2013250 (2012).","journal-title":"Virulence"},{"key":"26009_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fphar.2019.00092","volume":"10","author":"Y Huang","year":"2019","unstructured":"Huang, Y. et al. Acinetobacter baumannii ventilator-associated pneumonia: clinical efficacy of combined antimicrobial therapy and in vitro drug sensitivity test results. Front. Pharmacol. 10, 92 (2019).","journal-title":"Front. Pharmacol."},{"key":"26009_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1186\/s12879-016-2036-7","volume":"16","author":"A Bianco","year":"2016","unstructured":"Bianco, A. et al. Control of carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit of a teaching hospital in Southern Italy. BMC Infect. Dis. 16, 747 (2016).","journal-title":"BMC Infect. Dis."},{"key":"26009_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jinf.2011.12.008","volume":"64","author":"H Wisplinghoff","year":"2012","unstructured":"Wisplinghoff, H. et al. Nosocomial bloodstream infections due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States. J. Infect. 64, 282\u2013290 (2012).","journal-title":"J. Infect."},{"key":"26009_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1186\/s12879-022-07436-w","volume":"22","author":"A Vivo","year":"2022","unstructured":"Vivo, A. et al. Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: A retrospective cohort study. BMC Infect. Dis. 22, 491 (2022).","journal-title":"BMC Infect. Dis."},{"key":"26009_CR6","first-page":"1","volume":"9","author":"C Ayoub Moubareck","year":"2020","unstructured":"Ayoub Moubareck, C. & Hammoudi, H. D. Insights into Acinetobacter baumannii: A review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics (Basel, Switzerland) 9, 1 (2020).","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"26009_CR7","first-page":"15","volume":"3","author":"G Meletis","year":"2016","unstructured":"Meletis, G. Carbapenem resistance: Overview of the problem and future perspectives. Ther. Adv. Infect. Dis. 3, 15\u201321 (2016).","journal-title":"Ther. Adv. Infect. Dis."},{"key":"26009_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318\u2013327 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"26009_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink, R. G. et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 21, 213\u2013225 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"26009_CR10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40121-020-00351-0","volume":"9","author":"N Van Hise","year":"2020","unstructured":"Van Hise, N. et al. A real-world assessment of clinical outcomes and safety of eravacycline: A novel fluorocycline. Infect. Dis. Ther. 9, 1017\u20131028 (2020).","journal-title":"Infect. Dis. Ther."},{"key":"26009_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cmi.2019.03.014","volume":"25","author":"ET Piperaki","year":"2019","unstructured":"Piperaki, E. T., Tzouvelekis, L. S., Miriagou, V. & Daikos, G. L. Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment. Clin. Microbiol. Infect. 25, 951\u2013957 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"26009_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1183\/09031936.00156906","volume":"30","author":"FG Rios","year":"2007","unstructured":"Rios, F. G. et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur. Respir. J. 30, 307\u2013313 (2007).","journal-title":"Eur. Respir. J."},{"key":"26009_CR13","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.cmi.2021.01.020","volume":"27","author":"JY Feng","year":"2021","unstructured":"Feng, J. Y. et al. Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: A multi-centre observational study. Clin. Microbiol. Infect. 27, 1465\u20131473 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"26009_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13054-022-03947-9","volume":"26","author":"SH Wang","year":"2022","unstructured":"Wang, S. H. et al. The necessity of a loading dose when prescribing intravenous colistin in critically ill patients with CRGNB-associated pneumonia: A multi-center observational study. Crit. Care (London, England) 26, 91 (2022).","journal-title":"Crit. Care (London, England)"},{"key":"26009_CR15","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1038\/s41598-022-11061-7","volume":"12","author":"CY Chen","year":"2022","unstructured":"Chen, C. Y. et al. Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: A multicenter retrospective observational study. Sci. Rep. 12, 7501 (2022).","journal-title":"Sci. Rep."},{"key":"26009_CR16","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","volume":"31","author":"MM Levy","year":"2003","unstructured":"Levy, M. M. et al. 2001 SCCM\/ESICM\/ACCP\/ATS\/SIS international sepsis definitions conference. Crit. Care Med. 31, 1250\u20131256 (2003).","journal-title":"Crit. Care Med."},{"key":"26009_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcimb.2017.00055","volume":"7","author":"CR Lee","year":"2017","unstructured":"Lee, C. R. et al. Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front. Cell. Infect. Microbiol. 7, 55 (2017).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"26009_CR18","first-page":"1","volume":"10","author":"I Kyriakidis","year":"2021","unstructured":"Kyriakidis, I., Vasileiou, E., Pana, Z. D. & Tragiannidis, A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens (Basel, Switzerland) 10, 1 (2021).","journal-title":"Pathogens (Basel, Switzerland)"},{"key":"26009_CR19","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1111\/jam.15130","volume":"131","author":"M Nguyen","year":"2021","unstructured":"Nguyen, M. & Joshi, S. G. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital-acquired infections: A scientific review. J. Appl. Microbiol. 131, 2715\u20132738 (2021).","journal-title":"J. Appl. Microbiol."},{"key":"26009_CR20","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1469-0691.2006.01456.x","volume":"12","author":"L Poirel","year":"2006","unstructured":"Poirel, L. & Nordmann, P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 12, 826\u2013836 (2006).","journal-title":"Clin. Microbiol. Infect."},{"key":"26009_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijantimicag.2016.01.015","volume":"47","author":"SH Lob","year":"2016","unstructured":"Lob, S. H., Hoban, D. J., Sahm, D. F. & Badal, R. E. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int. J. Antimicrob. Agents 47, 317\u2013323 (2016).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"26009_CR22","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2147\/IDR.S166750","volume":"11","author":"M Asif","year":"2018","unstructured":"Asif, M., Alvi, I. A. & Rehman, S. U. Insight into Acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug Resist. 11, 1249\u20131260 (2018).","journal-title":"Infect. Drug Resist."},{"key":"26009_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jhm.2477","volume":"11","author":"MD Zilberberg","year":"2016","unstructured":"Zilberberg, M. D., Kollef, M. H. & Shorr, A. F. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study. J. Hosp. Med. 11, 21\u201326 (2016).","journal-title":"J. Hosp. Med."},{"key":"26009_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00042-16","volume":"30","author":"LY Hsu","year":"2017","unstructured":"Hsu, L. Y. et al. Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin. Microbiol. Rev. 30, 1\u201322 (2017).","journal-title":"Clin. Microbiol. Rev."},{"key":"26009_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/jgid.jgid_179_18","volume":"12","author":"I Jacob","year":"2020","unstructured":"Jacob, I., Rangappa, P., Thimmegowda, L. C. & Rao, K. A study of multidrug-resistant, colistin-only-sensitive infections in intubated and mechanically ventilated patients over 2 years. J. Glob. Infect. Dis. 12, 5\u201310 (2020).","journal-title":"J. Glob. Infect. Dis."},{"key":"26009_CR26","first-page":"271","volume":"75","author":"S Karakonstantis","year":"2020","unstructured":"Karakonstantis, S., Kritsotakis, E. I. & Gikas, A. Pandrug-resistant Gram-negative bacteria: A systematic review of current epidemiology, prognosis and treatment options. J. Antimicrob. Chemother. 75, 271\u2013282 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"26009_CR27","doi-asserted-by":"publisher","first-page":"106065","DOI":"10.1016\/j.ijantimicag.2020.106065","volume":"56","author":"S Karakonstantis","year":"2020","unstructured":"Karakonstantis, S. & Saridakis, I. Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications. Int. J. Antimicrob. Agents 56, 106065 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"26009_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2020.1794393","volume":"33","author":"S Karakonstantis","year":"2021","unstructured":"Karakonstantis, S. A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii. J. Chemother. (Florence, Italy) 33, 1\u201311 (2021).","journal-title":"J. Chemother. (Florence, Italy)"},{"key":"26009_CR29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s15010-021-01748-w","volume":"50","author":"S Karakonstantis","year":"2022","unstructured":"Karakonstantis, S., Ioannou, P. & Kofteridis, D. D. In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations. Infection 50, 569\u2013581 (2022).","journal-title":"Infection"},{"key":"26009_CR30","first-page":"1","volume":"10","author":"S Karakonstantis","year":"2021","unstructured":"Karakonstantis, S., Ioannou, P., Samonis, G. & Kofteridis, D. P. Systematic review of antimicrobial combination options for pandrug-resistant Acinetobacter baumannii. Antibiotics (Basel, Switzerland) 10, 1 (2021).","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"26009_CR31","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","volume":"48","author":"S Karakonstantis","year":"2020","unstructured":"Karakonstantis, S., Kritsotakis, E. & Gikas, A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: An approach based on the mechanisms of resistance to carbapenems. Infection 48, 835\u2013851 (2020).","journal-title":"Infection"},{"key":"26009_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jhin.2020.09.009","volume":"106","author":"S Karakonstantis","year":"2020","unstructured":"Karakonstantis, S., Gikas, A., Astrinaki, E. & Kritsotakis, E. I. Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients. J. Hosp. Infect. 106, 447\u2013453 (2020).","journal-title":"J. Hosp. Infect."},{"key":"26009_CR33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3855\/jidc.7203","volume":"10","author":"S Samrah","year":"2016","unstructured":"Samrah, S. et al. Impact of colistin-initiation delay on mortality of ventilator-associated pneumonia caused by A. baumannii. J. Infect. Dev. Countries 10, 1129\u20131134 (2016).","journal-title":"J. Infect. Dev. Countries"},{"key":"26009_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/f1000research.16517.1","volume":"8","author":"RR Watkins","year":"2019","unstructured":"Watkins, R. R. & Van Duin, D. Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteria. F1000Research 8, 1 (2019).","journal-title":"F1000Research"},{"key":"26009_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijid.2014.01.017","volume":"23","author":"J Xia","year":"2014","unstructured":"Xia, J. et al. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone\/sulbactam. Int. J. Infect. Dis. 23, 90\u201393 (2014).","journal-title":"Int. J. Infect. Dis."},{"key":"26009_CR36","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.ajic.2013.01.006","volume":"41","author":"YL Zheng","year":"2013","unstructured":"Zheng, Y. L. et al. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia. Am. J. Infect. Control 41, e59-63 (2013).","journal-title":"Am. J. Infect. Control"},{"key":"26009_CR37","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.cmi.2017.10.033","volume":"24","author":"CA Liang","year":"2018","unstructured":"Liang, C. A. et al. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin. Microbiol. Infect. 24, 908 (2018).","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26009-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26009-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T06:36:54Z","timestamp":1672814214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26009-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["26009"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-26009-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"11 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study waived the consent from participants approved by the Institutional Review Boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"140"}}